Inflammation-Related Gene Signature for Predicting the Prognosis of Head and Neck Squamous Cell Carcinoma.

Yilong Lu, Zengrong Jia
Author Information
  1. Yilong Lu: School of Stomatology, Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China.
  2. Zengrong Jia: Thyroid Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China.

Abstract

Purpose: The inflammatory response was associated with the prognosis of head and neck squamous cell carcinoma (HNSCC). This study aimed to perform a novel prognostic signature based on inflammation-related genes (IRGs) for a better understanding of the prognosis of HNSCC.
Patients and Methods: IRGs were obtained from The Cancer Genome Atlas (TCGA) database and the Gene Expression Omnibus (GEO) database. Functional enrichment analysis was performed to explore potential pathways. Univariate and multivariate Cox regression as well as the Least Absolute Shrinkage and Selection Operator (LASSO) were utilized to construct an IRGs-based prognostic model on TCGA database and the GEO database was utilized for outcome validation. The nomogram model was constructed based on independent prognostic factors after univariate and multivariate Cox regression. The immune cell infiltration level was analyzed via the Tumor Immune Estimation Resource (TIMER) database.
Results: In this study, we confirmed that 60% IRGs were abnormally expressed in HNSCC samples, and these were associated with important oncobiology. Then, a prognostic signature comprising 7 hub genes was generated based on TCGA database. The results were validated in 97 patients from GSE41613. A nomogram comprising risk score, age, M stage and N stage was generated to improve the accuracy of prognosis evaluation. The immune cell infiltration analysis suggested that 5 hub genes (ADGRE1, OLR1, TIMP1, GPR132 and CCR7) were negatively correlated with tumor purity and positively correlated with the infiltration of immune cells.
Conclusion: Our study established a novel signature consisting of 7 hub genes for the prognostic prediction in patients with HNSCC.

Keywords

References

  1. Asian Pac J Cancer Prev. ;18(4):1093-1104 [PMID: 28547946]
  2. Oral Oncol. 2014 Mar;50(3):178-88 [PMID: 24370206]
  3. CA Cancer J Clin. 2021 May;71(3):209-249 [PMID: 33538338]
  4. Cancer Cell Int. 2020 Jan 17;20:22 [PMID: 31988638]
  5. Cell Death Dis. 2021 Dec 17;13(1):4 [PMID: 34921134]
  6. Cancer Res. 2005 Aug 15;65(16):7071-80 [PMID: 16103054]
  7. Oral Oncol. 2018 Apr;79:55-63 [PMID: 29598951]
  8. Adv Protein Chem Struct Biol. 2020;119:199-245 [PMID: 31997769]
  9. Curr Opin Pharmacol. 2009 Aug;9(4):389-95 [PMID: 19570715]
  10. Biomed Res Int. 2021 Feb 10;2021:8824195 [PMID: 33628816]
  11. Front Genet. 2022 Jan 12;12:799933 [PMID: 35096015]
  12. J Med Chem. 2013 Aug 22;56(16):6279-96 [PMID: 23679915]
  13. Curr Opin Oncol. 2009 May;21(3):194-200 [PMID: 19363341]
  14. Br J Radiol. 2020 Apr;93(1108):20190154 [PMID: 31944856]
  15. J Biol Chem. 2012 Jan 27;287(5):3581-90 [PMID: 22158872]
  16. N Engl J Med. 2020 Jan 2;382(1):60-72 [PMID: 31893516]
  17. JAMA Oncol. 2017 Apr 01;3(4):524-548 [PMID: 27918777]
  18. PLoS One. 2011;6(5):e20277 [PMID: 21637860]
  19. Nat Rev Cancer. 2017 Jan;17(1):38-53 [PMID: 27932800]
  20. Comput Math Methods Med. 2020 Dec 28;2020:7397132 [PMID: 33456497]
  21. J Clin Oncol. 2015 Oct 10;33(29):3235-42 [PMID: 26351338]
  22. Exp Dermatol. 2019 Jan;28(1):66-71 [PMID: 30339292]
  23. BMC Cancer. 2020 Oct 20;20(1):1015 [PMID: 33081731]
  24. Biochim Biophys Acta Rev Cancer. 2021 Jan;1875(1):188499 [PMID: 33385485]
  25. Oncologist. 2019 Dec;24(12):1562-1569 [PMID: 31391295]
  26. Proc Natl Acad Sci U S A. 2017 Jan 17;114(3):580-585 [PMID: 28049847]
  27. Int Immunopharmacol. 2021 Sep;98:107789 [PMID: 34130150]
  28. BMC Cancer. 2010 Dec 12;10:677 [PMID: 21144000]
  29. Crit Rev Clin Lab Sci. 2008;45(3):291-338 [PMID: 18568853]
  30. Eur Arch Otorhinolaryngol. 2021 Sep;278(9):3467-3477 [PMID: 33449165]
  31. J Exp Clin Cancer Res. 2016 Sep 20;35(1):148 [PMID: 27644693]
  32. Lancet. 2014 Mar 1;383(9919):828-40 [PMID: 23927914]
  33. Lancet. 2008 May 17;371(9625):1695-709 [PMID: 18486742]
  34. Nature. 2008 Jul 24;454(7203):436-44 [PMID: 18650914]
  35. Lancet. 2001 Feb 17;357(9255):539-45 [PMID: 11229684]
  36. J Oral Maxillofac Surg. 2017 Dec;75(12):2562-2572 [PMID: 28618252]
  37. Adv Exp Med Biol. 2014;816:107-27 [PMID: 24818721]
  38. Cancer Manag Res. 2020 Feb 26;12:1427-1435 [PMID: 32161495]
  39. Nature. 2002 Dec 19-26;420(6917):860-7 [PMID: 12490959]
  40. Cancer Gene Ther. 2021 Nov;28(10-11):1088-1098 [PMID: 33402733]
  41. Oncotarget. 2016 Jun 21;7(25):38487-38499 [PMID: 27220887]
  42. Cell Mol Life Sci. 2014 Feb;71(4):659-72 [PMID: 23982756]
  43. Oral Oncol. 2005 Jan;41(1):70-6 [PMID: 15598588]
  44. Front Oncol. 2021 Mar 22;11:644416 [PMID: 33828988]
  45. Clin Cancer Res. 2007 Jun 1;13(11):3182-90 [PMID: 17545521]
  46. Mol Cancer Ther. 2006 Jan;5(1):8-19 [PMID: 16432158]
  47. J Allergy Clin Immunol. 2014 May;133(5):1439-47, 1447.e1-8 [PMID: 24530099]
  48. Cell Mol Immunol. 2022 Jan;19(1):59-66 [PMID: 34465885]
  49. J Stat Softw. 2011 Mar;39(5):1-13 [PMID: 27065756]
  50. Int J Biochem Cell Biol. 2022 Apr;145:106189 [PMID: 35219878]
  51. Lancet Oncol. 2014 Oct;15(11):e493-503 [PMID: 25281468]
  52. Signal Transduct Target Ther. 2021 Jan 1;6(1):2 [PMID: 33384409]
  53. Stat Med. 1997 Feb 28;16(4):385-95 [PMID: 9044528]
  54. J Inflamm Res. 2021 Aug 11;14:3809-3821 [PMID: 34408464]

Word Cloud

Created with Highcharts 10.0.0databaseHNSCCprognosticprognosisgenesTCGAcellstudysignaturebasedIRGsimmuneinfiltrationhubassociatednovelinflammation-relatedGeneGEOanalysismultivariateCoxregressionutilizedmodelnomogramcomprising7generatedpatientsstagecorrelatedPurpose:inflammatoryresponseheadnecksquamouscarcinomaaimedperformbetterunderstandingPatientsMethods:obtainedCancerGenomeAtlasExpressionOmnibusFunctionalenrichmentperformedexplorepotentialpathwaysUnivariatewellLeastAbsoluteShrinkageSelectionOperatorLASSOconstructIRGs-basedoutcomevalidationconstructedindependentfactorsunivariatelevelanalyzedviaTumorImmuneEstimationResourceTIMERResults:confirmed60%abnormallyexpressedsamplesimportantoncobiologyresultsvalidated97GSE41613riskscoreageMNimproveaccuracyevaluationsuggested5ADGRE1OLR1TIMP1GPR132CCR7negativelytumorpuritypositivelycellsConclusion:establishedconsistingpredictionInflammation-RelatedSignaturePredictingPrognosisHeadNeckSquamousCellCarcinomagene

Similar Articles

Cited By